J Korean Med Sci.  2017 May;32(5):810-816. 10.3346/jkms.2017.32.5.810.

A Single Center Analysis of the Positivity of Hepatitis B Antibody after Neonatal Vaccination Program in Korea

• Kim YJ
• Li P
• Hong JM
• Ryu KH
• Nam E
• Chang MS

• KMID: 2375082
• DOI: http://doi.org/10.3346/jkms.2017.32.5.810

Abstract

The antibody to hepatitis B surface antigen (anti-HBs) seropositivity rate after 3 doses of hepatitis B virus (HBV) vaccination during infancy period is known to be higher than 90%. However, a considerable number of vaccines do not form protective anti-HBs or chronologic decrease of anti-HBs. We retrospectively collected data of HBV serologic test results in 20,738 individuals from 2000 to 2015. After exclusion criteria were applied, 19,072 individuals were included. We analyzed the anti-HBs seropositivity rate, anti-HBs disappearance rate, anti-HBs positive seroconversion rate after receiving a booster vaccine, and the difference in anti-HBs positivity between the 2 groups; group A (born before 2005, while both recombinant vaccines and plasma-derived vaccines were used) and group B (born after 2005, when only recombinant vaccines were used by national regulation). The anti-HBs seropositivity rate was 55.8%, but there was a significant difference in the rate of seropositivity for anti-HBs between the group A and B (53.0% vs. 78.1%, P < 0.001). There was no significant age-adjusted difference in the mean seropositivity rate between the 2 groups (P = 0.058). In addition, the anti-HBs positivity rate was significantly lower in the group A as compared with the group B during infancy (83.1% vs. 92.1%, P < 0.001). A total of 1,106 anti-HBs-positive subjects underwent serologic tests more than twice. Of these, 217 subjects (19.6%) showed anti-HBs disappearance. After booster vaccinations, 87.4% (83/95) achieved seroconversion from seronegative to seropositive. Our results highlight the importance of lifelong protection against HBV and the possible necessity of booster vaccination after adolescent period.

Keyword

Hepatitis B antibody; South Korea; Booster; Plasma-derived Vaccine; Recombinant DNA Vaccine; Children

MeSH Terms

Adolescent
Child
Hepatitis B Surface Antigens
Hepatitis B virus
Hepatitis B*
Hepatitis*
Humans
Korea*
Retrospective Studies
Seroconversion
Serologic Tests
Vaccination*
Vaccines
Vaccines, Synthetic
Hepatitis B Surface Antigens
Vaccines
Vaccines, Synthetic

Figure

• 

  Fig. 1 The anti-HBs seropositivity rate depending on the age. The anti-HBs seropositivity rate reached the highest level (90.0%) at the age of < 12 months old. Until the age of 15 years old thereafter, however, it was decreased and then reached the lowest level of 43.5%. Since the age of 16 years old, however, it was gradually increased. Anti-HBs = antibody to hepatitis B surface antigen.

• 

  Fig. 2 The rate of seroconversion from seropositive to seronegative status depending on the age. A total of 1,106 subjects aged between 1 and 25 years old underwent serologic tests more than twice. Of these, 217 subjects (19.6%) achieved seroconversion from seropositive to seronegative status. There was an age-dependent increase in the rate of seroconversion from seropositive to seronegative status; it reached the highest level (45.5%) at the age of 9 years old. Thereafter, however, it was decreased. Anti-HBs = antibody to hepatitis B surface antigen.

Reference

1. Chun BY, Lee MK, Rho YK. The prevalence of hepatitis B surface antigen among Korean by literature review. Korean J Epidemiol. 1992; 14:70–78.

2. Choe YH, Seo JK, Yun JH, Lee HS. Recent changes in prevalence of hepatitis B viral markers in preschool children in Seoul, 1995. J Korean Pediatr Soc. 1996; 39:1254–1259.

3. Jang MK, Lee JY, Lee JH, Kim YB, Kim HY, Yoo JY. The investigation for the change of HBsAg positive rate of grade junior high high-schoolers for recent 3 years in Kangwon province. Korean J Med. 2000; 58:608–615.

4. Choe BH. The epidemiology and present status of chronic hepatitis B in Korean children. Korean J Pediatr. 2008; 51:696–703.

5. Roberts H, Kruszon-Moran D, Ly KN, Hughes E, Iqbal K, Jiles RB, Holmberg SD. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hepatology. 2016; 63:388–397.

6. Park SH. Trends in the seroprevalence of hepatitis B surface antigen in the South Korean population. Int J Infect Dis. 2012; 16:e669–e672.

7. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol. 2012; 4:74–80.

8. Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology. 2010; 53:20–28.

9. Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci. 2002; 17:457–462.

10. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012; 57:730–735.

11. Chen SM, Kung CM, Yang WJ, Wang HL. Efficacy of the nationwide hepatitis B infant vaccination program in Taiwan. J Clin Virol. 2011; 52:11–16.

12. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011; 53:68–75.

13. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, Khristova M, Zanis C, Peters H, Margolis HS. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005; 142:333–341.

14. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011; 17:87–95.

15. Lu CY, Chiang BL, Chi WK, Chang MH, Ni YH, Hsu HM, Twu SJ, Su IJ, Huang LM, Lee CY. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology. 2004; 40:1415–1420.

16. Chen TW. Paths toward hepatitis B immunization in South Korea and Taiwan. Clin Exp Vaccine Res. 2013; 2:76–82.

17. Chung WK, Sun HS, Chung KW, Kim BS, Min BK, Prince AM. Safety and immunogenicity of a new heat-inactivated hepatitis B virus vaccine in adult recipients. Vaccine. 1987; 5:175–178.

18. Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013; 10:239.

19. Gringeri A. Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus. 2011; 9:366–370.

20. Hernández-Bernal F, Aguilar-Betancourt A, Aljovin V, Arias G, Valenzuela C, de Alejo KP, Hernández K, Oquendo O, Figueredo N, Figueroa N, et al. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults. Hum Vaccin. 2011; 7:1026–1036.

21. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow L, Fiore AE, Bell BP, Hennessy TW. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009; 200:1390–1396.

22. Sim JG, Seo JK, Suh SJ. Prevalence and its changes of hepatitis B viral markers from 1988 to 1993 in Korean Children. J Korean Pediatr Soc. 1995; 38:1535–1539.

23. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology. 2007; 132:1287–1293.

24. Kim H, Shin AR, Chung HH, Kim MK, Lee JS, Shim JJ, Kim BH. Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med. 2013; 28:413–419.

25. Sung L, Heurter H, Zokvic KM, Ford-Jones EL, Weitzman SS, Freeman R, Dupuis LL, Scheifele DW. Practical vaccination guidelines for children with cancer. Paediatr Child Health. 2001; 6:379–383.

26. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Crasta PD, Hardt K. Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers. Hum Vaccin Immunother. 2012; 8:896–904.

27. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012; 16:e82–e88.

28. Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol. 2004; 2:941–945.

29. Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, Lee CM, Lu SN. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine. 2009; 27:1858–1862.

30. Lu JJ, Cheng CC, Chou SM, Hor CB, Yang YC, Wang HL. Hepatitis B immunity in adolescents and necessity for boost vaccination: 23 years after nationwide hepatitis B virus vaccination program in Taiwan. Vaccine. 2009; 27:6613–6618.

31. Zanetti AR, Mariano A, Romanò L, D’Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005; 366:1379–1384.

32. Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad. 2006; 18:4–9.

33. Cossio-Gil Y, Martínez-Gómez X, Campins-Martí M, Rodrigo-Pendás JÁ, Borruel-Sainz N, Rodríguez-Frías F, Casellas-Jordà F. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. J Gastroenterol Hepatol. 2015; 30:92–98.

34. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev. 2000; 13:385–407.

35. Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, Chiu TY, Huang LM, Chen CJ, Chen DS. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology. 2010; 51:1547–1554.

36. Hartal M, Yavnai N, Galor I, Avramovich E, Sela T, Kayouf R, Tzurel-Ferber A, Greenberg LJ, Halperin T, Levine H. Seroprevalence of anti-HBs antibodies at young adulthood, before and after a booster vaccine dose, among medical personnel vaccinated in infancy. Vaccine. 2015; 33:4878–4885.